DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Recent trends reveal a sharp rise in cancer cases in India, with younger patients and a lack of effective screening programs ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

GSK (GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. Read more here.

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...